Stack AI
AI agents are designed to engage with users, answer inquiries, and accomplish tasks by leveraging data and APIs. These intelligent systems can provide responses, condense information, and derive insights from extensive documents. They also facilitate the transfer of styles, formats, tags, and summaries between various documents and data sources. Developer teams utilize Stack AI to streamline customer support, manage document workflows, qualify potential leads, and navigate extensive data libraries. With just one click, users can experiment with various LLM architectures and prompts, allowing for a tailored experience. Additionally, you can gather data, conduct fine-tuning tasks, and create the most suitable LLM tailored for your specific product needs. Our platform hosts your workflows through APIs, ensuring that your users have immediate access to AI capabilities. Furthermore, you can evaluate the fine-tuning services provided by different LLM vendors, helping you make informed decisions about your AI solutions. This flexibility enhances the overall efficiency and effectiveness of integrating AI into diverse applications.
Learn more
Castor EDC
Castor is an innovative clinical trial platform designed to simplify data management through electronic data capture (EDC), eConsent, and patient-reported outcomes (ePRO). Its flexible and user-friendly interface allows researchers to collect, manage, and analyze clinical data efficiently across multiple sites and remote patients. Castor’s tools are specifically designed to support decentralized clinical trials (DCTs), enabling real-time data monitoring, remote recruitment, and seamless patient engagement. The platform ensures full regulatory compliance, including HIPAA, GDPR, and 21 CFR Part 11, and is certified for ISO standards. With more than 50,000 global users, Castor continues to improve the speed and quality of clinical trials through integrated, scalable solutions that reduce administrative burdens and accelerate research.
Learn more
Altis Labs Nota
Altis Labs has introduced Nota, a groundbreaking platform aimed at improving the efficiency of therapeutic research and development in the clinical field. By leveraging artificial intelligence, Nota assesses imaging data to forecast patient outcomes, enabling sponsors to better concentrate on their most viable therapies. This cutting-edge tool equips researchers with the ability to utilize imaging data from clinical trials, access predictive biomarkers, and accelerate research initiatives on a broader scale. With Altis' cloud-based software that employs deep learning techniques, biopharma companies can achieve comprehensive outcome predictions at the levels of individual images, patients, and entire cohorts, thereby enhancing the design of clinical trials and boosting confidence in predicting clinical endpoints. The insights provided by Nota hold the potential to significantly shorten development timelines, reduce drug development costs, and increase the likelihood of success in clinical trials across diverse therapeutic areas. Furthermore, Nota signifies a major leap forward in the fusion of technology with clinical research, ultimately paving the way for more streamlined and effective drug development methodologies. This innovation not only promises to transform the landscape of clinical trials but also aims to improve patient outcomes in the long run.
Learn more
Genomenon
Pharmaceutical firms need a wealth of genomic information to successfully execute precision medicine strategies; however, they often utilize only a fraction—around 10%—of the total data at their disposal for decision-making. Genomenon offers an extensive database to counter this limitation. Their Prodigy™ Patient Landscapes deliver a cost-effective and efficient approach for conducting natural history research, which is crucial for developing treatments for rare conditions by expanding the understanding of both past and future health data. Employing a sophisticated AI-driven process, Genomenon meticulously analyzes each patient referenced in the medical literature much faster than traditional methods. It is essential to capture all pertinent insights by examining every genomic biomarker highlighted in scholarly articles. Each scientific assertion is backed by solid evidence sourced from medical literature, enabling researchers to identify all genetic factors and pinpoint variants classified as pathogenic according to ACMG clinical criteria, thus streamlining the creation of targeted therapies. By adopting this thorough strategy, pharmaceutical companies can significantly boost their research efficiency and, in turn, enhance patient outcomes. This innovative model not only fosters advancements in drug development but also contributes to a deeper understanding of genetic influences on health.
Learn more